CD19-targetd CAR-T

Phase 1Cell therapy

CChongqing Precision Biotech Co., Ltd

CD19-targetd CAR-T is one of 3 biologic programs targeting Juvenile Dermatomyositis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Juvenile DermatomyositisRecruiting

Juvenile DermatomyositisPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Juvenile Dermatomyositis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Approved

1 2

CD19-targetd CAR-T

CChongqing Precision Biotech Co., Ltd

Phase 1

1 3

Anti-CD19 UCAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Juvenile Dermatomyositis

NCT06569472

Clinical

Trials by Indication[1]

Juvenile Dermatomyositis1 trial

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06569472·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD19-targetd CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19-targetd CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19-targetd CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: CChongqing Precision Biotech Co., Ltd

CD19-targetd CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Juvenile Dermatomyositis1 trial

References

Drug Info

Quick Facts

Related News